London, Feb 8, 2026, 18:24 GMT — The market has closed.
- AstraZeneca finished Friday in London trading with a 0.9% gain at £141.04. In New York, shares climbed 3.2% to $193.23.
- Investors get the full-year and Q4 numbers Tuesday. What comes next? All eyes on the 2026 outlook.
- Fresh U.S. pressure on drug pricing is back in focus for investors following the TrumpRx rollout.
Shares of AstraZeneca PLC (AZN.L) closed Friday at £141.04 in London, marking a 0.9% gain after moving between £138.44 and £141.12 during the session. In New York, the stock finished 3.2% higher at $193.23. (AstraZeneca)
AstraZeneca will release its Full Year and Q4 2025 numbers at 0700 GMT Tuesday, followed by an investor webcast at 1145 GMT. With shares holding steady, investors are likely to zero in on 2026 guidance—possibly overshadowing whatever the latest quarter brings. (AstraZeneca)
UK stocks are heading into the week still riding a risk-on surge. The FTSE 100 booked a 0.6% gain Friday, marking its second week in the green. Banks did most of the heavy lifting after the Bank of England hinted at possible rate cuts should inflation keep sliding, according to Reuters. (Reuters)
Hargreaves Lansdown points to consensus numbers for AstraZeneca: revenue is expected to climb 8.4% to $58.6 billion, with operating profit projected at $18.3 billion, up 7.7%. Derren Nathan, who leads equity research at the firm, flagged “guidance for 2026 and beyond will be the key metrics to monitor.” (Hargreaves Lansdown)
Drug pricing has crept back into view for traders as Washington pushes the issue again. TrumpRx.gov went live, but so far it lists fewer than 45 medicines, Reuters noted. The site doesn’t actually sell drugs—it’s just coupons or links to manufacturer pages. Discounts? They run from 33% off up to more than 90% off the list. Trump claimed 16 major drugmakers agreed to “most-favoured nation” terms, pegging U.S. prices to the lowest in peer countries. But by Friday, Reuters found just five companies had products on the platform. In an email, Vanderbilt’s Stacie Dusetzina called it “a small proportion of people may be able to find a better deal.” (Reuters)
The market’s nerves were on display, despite uncertainty over just how far the programme will go. Friday in Tokyo, Japanese pharma stocks dropped after TrumpRx’s debut. Sumitomo Pharma slid 4.5%, while Takeda lost 1.5%, according to Reuters. (Reuters)
AstraZeneca’s shift in its listing structure has drawn extra attention from U.S. investors. Earlier this month, the company kicked off trading its ordinary shares on the NYSE, part of a move to align its listings across New York, London, and Stockholm. Chair Michel Demaré called the step one that “gives broader access to the largest capital market in the world.” In that same release, AstraZeneca pointed to new pipeline readouts from last year, saying those represented a peak revenue opportunity north of $10 billion, and reiterated confidence in targeting $80 billion in annual revenue by 2030 with plans to launch 20 new medicines. (AstraZeneca)
But there’s a risk here, too. If the outlook for 2026 turns cautious, or if new signs emerge that discounting is filtering out past just a handful of drugs, the stock could face swift pressure.
London trading picks back up Monday. Focus snaps to Tuesday—results hit at 0700 GMT, followed by the investor call at 1145 GMT. Investors want direction on U.S. pricing, fresh guidance, and any word on whether management is standing by those long-term growth targets.
